CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin

Metastatic Colorectal Cancer Clinical Trial

Official title:

A Phase 2 Open-label Randomized, Controlled Trial of CS-1008 in Combination With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Oxaliplatin Based Regimen

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00969033
• Other study ID #: CS1008-A-E203
• Status: Terminated
• Phase: Phase 2
• First received: August 28, 2009
• Last updated: January 30, 2012
• Start date: July 2009
• Est. completion date: December 2011

Study information

• Verified date: January 2012
• Source: Daiichi Sankyo Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: National Health ServiceUnited Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the effect of CS-1008 in combination with irinotecan compared to irinotecan alone on Progression-Free Survival (PFS) in subjects with metastatic or advanced colorectal cancer (CRC) who have failed oxaliplatin-based first-line treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed CRC which is now metastatic and after failure of oxaliplatin-based first-line treatment.

• At least 18 years of age.

• ECOG performance status =< 1.

• Measurable disease based on RECIST criteria.

• Adequate organ and bone marrow function as evidenced by:

• Hemoglobin >= 9.0 g/dL (may be transfused to this level)

• Absolute neutrophil count (ANC) >= 1.5 x 109/L

• Platelet count >= 100 x 109/L

• Serum creatinine =< upper limit of normal (ULN) or creatinine clearance > 50 mL/min

• AST <= 2.5 x ULN in subjects with no liver metastasis and <= 5.0 x ULN in subjects with liver metastasis

• Total bilirubin < 1.5 x ULN

• Men and women of childbearing potential must be willing to consent to using effective contraception (e.g., hormonal contraceptives, bilateral tubal ligation, barrier with spermicide, intrauterine device) while on treatment and for 3 months thereafter.

• All female subjects of childbearing potential must have a negative pregnancy test (serum or urine) result within 7 days before initiating study treatment.

• Subjects must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an IEC/IRB approved ICF before performance of any study specific procedures or tests.

• Subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

• Anticipation of need for a major surgical procedure or radiotherapy (RT) during the study.

• Treatment with chemotherapy hormonal therapy, RT, minor surgery, or any investigational agent within 4 weeks before study enrollment. Treatment with nitrosoureas, mitomycin C, immunotherapy, biological therapy, or major surgery within six weeks prior to study enrollment. St John's Wort within 2 weeks prior to study enrollment or during the study.

• History of any of the following conditions within 6 months before study enrollment:

• Clinically significant myocardial infarction or severe/unstable angina pectoris

• New York Heart Association (NYHA) class III or IV congestive heart failure (Section 17.2)

• Clinically significant cerebrovascular accident, transient ischemic attack or pulmonary embolism- Clinically significant pulmonary disease (e.g., severe chronic obstructive pulmonary disease or asthma)

• Presence of any of the following: Symptomatic brain metastasis; an uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis.

• Clinically significant active infection that requires antibiotic therapy or Human Immunodeficiency Virus (HIV) positive subjects receiving antiretroviral therapy.

• History of malignancy other than CRC, unless there is the expectation that the malignancy has been cured, and tumor specific treatment for the malignancy has not been administered within the previous 5 years. Exceptions to this are non melanotic cancer of the skin and adequately treated carcinoma of the cervix-in-situ.

• Previous treatment with CS 1008, other agonistic DR5 antibody agents, or TRAIL agents.

• History of active chronic inflammatory bowel disease and/or bowel obstruction within the last 3 months.

• Pregnant or breast feeding.

• Known history of hypersensitivity reactions to irinotecan or to one of the excipients.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Metastatic Colorectal Cancer

Intervention

Drug:
• CS-1008
CS-1008
• irinotecan
irinotecan

Locations

Country	Name	City	State
United Kingdom	Royal United Hospital Bath	Bath
United Kingdom	Clatterbridge Hospital	Bebington	Wirral
United Kingdom	Broomfield Hospital	Chelmsford	Essex
United Kingdom	Russels Hall Hospital	Dudley
United Kingdom	Leicester Royal Infirmary	Leicester
United Kingdom	Mount Vernon Hospital	Northwood	Middlesex
United Kingdom	Nottingham City Hospital	Nottingham	Notts
United Kingdom	Chrichill Hospital	Oxford	Oxon
United Kingdom	Royal Marsden Hospital	Sutton	Surrey

Sponsors (1)

Lead Sponsor	Collaborator
Daiichi Sankyo Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the difference in progression-free survival (PFS) for CS-1008 administered in combination with irinotecan and irinotecan alone.		1 year	No
Secondary	Determine the difference in overall survival for CS-1008 administered in combination with irinotecan and irinotecan alone.		1 year	No
Secondary	Determine the difference in median survival for CS-1008 administered in combination with irinotecan and irinotecan alone.		1 year	No
Secondary	Determine the difference in objective response rate (ORR) for CS-1008 administered in combination with irinotecan and irinotecan alone.		1 year	No
Secondary	To determine the Incidence of anti- CS-1008 antibody formation.		1 year	No